Skip to content

Effect of butorphanol intranasal administration on sufentanil-induced cough response during induction of general anesthesia

Effect of butorphanol intranasal administration on sufentanil-induced cough response during induction of general anesthesia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100049699
Enrollment
Unknown
Registered
2021-08-08
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adverse reactions related to narcotic drugs

Interventions

Control group:None
Group V :Butorphanol 1 mg intravenously 2 minutes before induction
Group NL :Butorphanol 1mg intranasal 15 minutes before induction
Group NH :Butorphanol 2mg intranasal 15 minutes before induction

Sponsors

Hu'nan Provincial People's Hospital (The First Affiliate Hospital of Hu'nan Normal University )
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years; 2. Patients receiving elective general anesthesia; 3. ASA score is I-III; 4. 18.5 kg/m^2<BMI<30kg/m^2; 5. Clearly understand and voluntarily participate in the research, and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Opioid-tolerant patients; 2. Patients who are dependent on narcotine; 3. Pregnant and lactating patients; 4. Those who are mentally ill or unable to cooperate for other reasons; 5. Patients with central nervous system disease before surgery; 6. History of chronic pain (pain symptoms for more than 3 months); 7. Patients taking sedatives, antidepressants or drugs that excite the central nervous system before surgery; 8. Patients with a history of allergies; 9. Patients with bronchial asthma or chronic obstructive pulmonary disease before surgery; 10. Patients who have taken steroids and bronchodilators in the past two weeks; 11. Those with upper respiratory tract infection within the past two weeks; 12. History of PONV or motion sickness; 13. Patients with myocardial infarction, ventricular dysfunction, and coronary insufficiency; 14. Participate in other drug clinical investigators within the past three months.

Design outcomes

Primary

MeasureTime frame
Incidence rate of coughing;

Secondary

MeasureTime frame
Severity of occurrence;Vital signs;Intraoperative blood loss;Intraoperative urine output;Intraoperative fluid input;Postoperative extubation time;Ramsay sedation score;Rest-lessness score;Postoperative nausea and vomiting score;

Countries

China

Contacts

Public ContactPan Bingbing

Hu'nan Provincial People's Hospital (The First Affiliate Hospital of Hu'nan Normal University )

22058876@qq.com+86 13787245546

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026